Thyroglobulin in differentiated thyroid cancer

Clin Chim Acta. 2015 Apr 15:444:310-7. doi: 10.1016/j.cca.2014.10.035. Epub 2014 Oct 29.

Abstract

Identification of differentiated thyroid cancer (DTC) is becoming increasingly common. Patients usually have an excellent prognosis. Most undergo total thyroidectomy, radioiodine ablation and treatment with suppressive doses of levothyroxine. Patients require long term follow-up which includes measurement of serum thyroglobulin (Tg). Interpretation of serum Tg requires knowledge of the concurrent thyroid stimulating hormone (TSH) concentration, as secretion is TSH dependant, and an awareness of the limitations of the methods used to measure it. These limitations include the heterogeneity of Tg in serum, the ability of assays to recognise forms of Tg secreted by a tumour, assay biases and not least the potential for interference in immunoassays for Tg from endogenous thyroglobulin antibodies (TgAbs) in patient serum. This review considers what the clinician wants to know and how Tg results can be interpreted in light of an awareness of assay limitations.

Keywords: Differentiated thyroid cancer; Thyroglobulin.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunoassay
  • Thyroglobulin / blood*
  • Thyroid Neoplasms / blood*

Substances

  • Thyroglobulin